Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZLAB
stocks logo

ZLAB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
127.07M
+16.5%
-0.429
-46.44%
130.30M
+22.36%
-0.230
-48.89%
139.90M
+27.21%
-0.180
-51.35%
Estimates Revision
The market is revising Downward the revenue expectations for Zai Lab Limited (ZLAB) for FY2025, with the revenue forecasts being adjusted by -17.15% over the past three months. During the same period, the stock price has changed by -44.33%.
Revenue Estimates for FY2025
Revise Downward
down Image
-17.15%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+18.93%
In Past 3 Month
Stock Price
Go Down
down Image
-44.33%
In Past 3 Month
Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is 53.73 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is 53.73 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.770
sliders
Low
25.70
Averages
53.73
High
74.00
Current: 17.770
sliders
Low
25.70
Averages
53.73
High
74.00
Goldman Sachs
downgrade
2025-11-03
Reason
Goldman Sachs
Price Target
2025-11-03
downgrade
Reason
Goldman Sachs analysts removed Zai Lab from the firm's APAC Conviction List as part of its monthly update.
Citi
Buy
maintain
$66 -> $69
2025-08-11
Reason
Citi
Price Target
$66 -> $69
2025-08-11
maintain
Buy
Reason
Citi raised the firm's price target on Zai Lab to $69 from $66 and keeps a Buy rating on the shares. The firm updated the company's model post the Q2 report.
Cantor Fitzgerald
Li Watsek
Buy
Reiterates
n/a
2025-03-27
Reason
Cantor Fitzgerald
Li Watsek
Price Target
n/a
2025-03-27
Reiterates
Buy
Reason
JP Morgan
Anupam Rama
Buy
Maintains
$44 → $51
2025-03-13
Reason
JP Morgan
Anupam Rama
Price Target
$44 → $51
2025-03-13
Maintains
Buy
Reason
JPMorgan raised the firm's price target on Zai Lab to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space.
Scotiabank
Louise Chen
Buy
Initiates
$55
2025-03-07
Reason
Scotiabank
Louise Chen
Price Target
$55
2025-03-07
Initiates
Buy
Reason
B of A Securities
David Lim
Strong Buy
to
Hold
Downgrades
$29 → $36
2025-03-03
Reason
B of A Securities
David Lim
Price Target
$29 → $36
2025-03-03
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zai Lab Ltd (ZLAB.O) is -18.59, compared to its 5-year average forward P/E of -18.35. For a more detailed relative valuation and DCF analysis to assess Zai Lab Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.35
Current PE
-18.59
Overvalued PE
2.28
Undervalued PE
-38.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-14.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.34
Undervalued EV/EBITDA
-28.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
21.26
Current PS
0.00
Overvalued PS
48.28
Undervalued PS
-5.75
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ZLAB News & Events

Events Timeline

(ET)
2025-12-08
07:20:00
Zai Lab Initiates Global Clinical Trial for ZL-1503
select
2025-12-07 (ET)
2025-12-07
12:40:00
Zai Lab's Drugs Renewed in 2025 National Reimbursement Drug List
select
2025-11-06 (ET)
2025-11-06
08:22:55
Zai Lab projects FY25 revenue to reach a minimum of $460M, while consensus estimates stand at $556.41M.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-07Newsfilter
Zai Lab Updates Three Medicines in China's National Reimbursement Drug List
  • Drug Renewals: Zai Lab's VYVGART, NUZYRA, and ZEJULA have been successfully renewed in the 2025 National Reimbursement Drug List by China's NHSA, reflecting their strong clinical value and expected to significantly reduce the disease burden on patients.
  • Expanded Market Access: With this update, Zai Lab now has six products included in the NRDL, enhancing patient access to high-quality novel medicines and demonstrating the company's ongoing commitment to innovation in pharmaceuticals.
  • Addressing Treatment Needs: VYVGART targets anti-AChR antibody-positive patients with generalized myasthenia gravis, NUZYRA is indicated for community-acquired pneumonia and acute bacterial skin infections, while ZEJULA offers maintenance therapy for platinum-sensitive ovarian cancer patients, fulfilling urgent market demands for new therapies in China.
  • Strategic Implications: Zai Lab will continue to enhance the accessibility and affordability of its medicines, enabling more patients to benefit from innovative therapies as early as possible, thereby solidifying its leadership position in China's biopharmaceutical market.
[object Object]
Preview
8.5
12-07Businesswire
Zai Lab Secures Inclusion of Six Medicines in 2025 NRDL
  • NRDL Update: Zai Lab's VYVGART, NUZYRA, and ZEJULA have successfully been renewed for inclusion in the 2025 National Reimbursement Drug List (NRDL), reflecting the company's strong clinical value and significantly reducing the financial burden on patients.
  • Increased Product Diversity: This update brings Zai Lab's total products in the NRDL to six, enhancing the company's competitive edge in the Chinese market and better addressing the demand for high-quality novel medicines among patients.
  • Accelerated Market Access: By including these innovative drugs in the NRDL, Zai Lab not only improves patient accessibility but also potentially increases market share through enhanced treatment outcomes, driving future revenue growth.
  • Commitment to Innovation: Zai Lab emphasizes its ongoing commitment to enhancing the accessibility and affordability of its medicines, ensuring that more patients can benefit from innovative therapies as early as possible, which underscores the company's long-term dedication to the Chinese healthcare market.
[object Object]
Preview
9.0
12-07Yahoo Finance
Zai Lab Reveals Changes to China's National Drug Reimbursement List

  • Renewal of Medicines: Zai Lab announced the renewal of VYVGART, NUZYRA, and ZEJULA in China's National Reimbursement Drug List, enhancing patient access to these innovative treatments for conditions like generalized myasthenia gravis, community-acquired bacterial pneumonia, and ovarian cancer.

  • Impact on Patients: The inclusion of these drugs in the NRDL is expected to reduce the disease burden on patients in China, allowing broader access to high-quality medicines and improving treatment outcomes for serious health conditions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zai Lab Ltd (ZLAB) stock price today?

The current price of ZLAB is 17.77 USD — it has decreased -0.28 % in the last trading day.

arrow icon

What is Zai Lab Ltd (ZLAB)'s business?

Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.

arrow icon

What is the price predicton of ZLAB Stock?

Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is 53.73 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zai Lab Ltd (ZLAB)'s revenue for the last quarter?

Zai Lab Ltd revenue for the last quarter amounts to 116.10M USD, increased 13.52 % YoY.

arrow icon

What is Zai Lab Ltd (ZLAB)'s earnings per share (EPS) for the last quarter?

Zai Lab Ltd. EPS for the last quarter amounts to -0.03 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zai Lab Ltd (ZLAB)'s fundamentals?

The market is revising Downward the revenue expectations for Zai Lab Limited (ZLAB) for FY2025, with the revenue forecasts being adjusted by -17.15% over the past three months. During the same period, the stock price has changed by -44.33%.
arrow icon

How many employees does Zai Lab Ltd (ZLAB). have?

Zai Lab Ltd (ZLAB) has 1869 emplpoyees as of December 13 2025.

arrow icon

What is Zai Lab Ltd (ZLAB) market cap?

Today ZLAB has the market capitalization of 1.97B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free